Comments on: A Busy Month for Immunogen (Part I)

By: Ohad Hammer

Ohad Hammer — Mon, 07 Dec 2009 07:08:33 +0000

Thanks.
I think that somewhere in between ( perhaps 200-300M in the US). But I suspect T-DM1’s use will be broader than just third line patients even before 2nd line approval.

ohad

By: biotech_fan

biotech_fan — Sun, 06 Dec 2009 17:15:00 +0000

great write up. any idea what kind of $s the 3rd line indication would generate? are we talkin 50M for the 3rd line at 100% penetration or 500M?

By: Ohad Hammer

Ohad Hammer — Sat, 05 Dec 2009 08:01:46 +0000

I agree with you John.
Safety has always been an important aspect, now more than ever. Again, the big question is what the PFS will be vs. Tykerb+Xeloda.

Ohad

By: Ohad Hammer

Ohad Hammer — Sat, 05 Dec 2009 07:59:56 +0000

Thanks, Alvaro.

By: john voermans

john voermans — Sat, 05 Dec 2009 01:29:23 +0000

“comparable PFS could be enough for approval.”

Isn’t it true that recently debilitating side efffects of new drugs are coming under much greater scrutiny by FDA then used to be the case?
It is my believe that even if T-DM1 reports in with comparable PFS vs Tykerb/Xeloda, improvements to patient’s quality of life while on a T-DM1 regimen are such that the FDA will approve this new agent.

By: Alvaro

Alvaro — Fri, 04 Dec 2009 15:19:07 +0000

i like you blog, youve just got yourself a new follower.
alvaro

By: Ohad Hammer

Ohad Hammer — Thu, 03 Dec 2009 07:43:44 +0000

Sorry, cannot comment on PLX

By: sam

sam — Thu, 03 Dec 2009 06:31:35 +0000

plx shareholders appear disappointed since the stock dropped more than 10%

By: Ohad Hammer

Ohad Hammer — Wed, 02 Dec 2009 07:09:06 +0000

Thanks a lot, Manish.

ohad

By: Manish

Manish — Wed, 02 Dec 2009 03:21:08 +0000

Congratulations on PLX/PFE deal. Good things to come to you and your company. Also great post on IMGN as always.